Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Financial Information of Reportable Segment

Financial information of the Company’s reportable segment for the three months ended March 31, 2025 and 2024 are as follows (in thousands):

	Three Months Ended March 31,
	2025			2024
Research and development ("R&D") programs:
CLN-978	$	4,673		$	1,503
CLN-619		6,118			4,286
Zipalertinib		10,160			8,288
CLN-049		3,895			1,476
CLN-617		1,793			1,012
CLN-418		—			3,072
Early-stage programs		1,022			1,361
Total R&D program expense		27,661			20,998
Equity-based compensation		9,374			8,227
R&D personnel and operations		9,831			6,488
G&A personnel		3,489			3,952
License agreement obligations		38			25
Other segment expenses(1)		4,603			3,299
Loss from operations		(54,996	)		(42,989	)
Other income (expense):
Interest income		6,580			5,693
Other income (expense), net		(85	)		(44	)
Net loss		(48,501	)		(37,340	)
Net loss attributable to noncontrolling interests		—			(192	)
Net loss attributable to Cullinan	$	(48,501	)	$	(37,148	)

(1)Other segment expenses for the three months ended March 31, 2025 and 2024 include legal fees relating to patent and corporate matters; professional fees for accounting, auditing, tax, and administrative consulting services; insurance costs; marketing expenses; depreciation; and other operating costs.